Annotated bibliography 3

  • 63 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
63
On Slideshare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Annotated Bibliography 3:Alhamdani MSS, Youns M, Buchholz M, Gress TM, Beckers MC, Maréchal D, Bauer A, Schrӧder C,Hoheisel JD. 2012. Immunoassay-based proteome profiling of 24 pancreatic cancer cell lines. J. ofProteamics [Internet]; [cited 2012 Oct 25]. 75(12):3747-3759. Doi10.1016/j.jprot.2012.04.042. Available at:http://www.sciencedirect.com/science/article/pii/S1874391912002631 There is little information about diagnosis of pancreatic ductal. It is one of the biggest causes of deathhaving a mortality almost equal to its incidence. This investigation is about 24 pancreatic cancer cell lines.Its purpose is to determine more about the disease characteristics, based on the identification of cellularvariations and proteins. In the investigation two controls were used, the HUVEC (Human UmbilicalEndothelial Cell) and the HPDE (Human Pancreatic Duct Epithelial,). The second one has a recentemergence. After establishing the controls, the 26 pancreatic cell lines (the 24 experimental and 2 controls)were subjected to a microarray method to register the expression of 741 proteins. These proteins werecompared with the cancer cell lines. The results of the comparisons demonstrated the changes of expressionin the pancreatic cancer cells. After the analysis, the cancer lines were classified by their original location,primary tumor, liver metastases and ascites. In conclusion, the research provides molecular information tohelp in the development of therapies and treatment of metastatic cells.The primary article presents many details related to the performance of pancreatic carcinoma, such as theidentification of new proteins. With the results, therapies that actually work can be developed for the patientsbecause the ones that exist at this moment are not effective. This performance is possible because when thenew proteins are identified and examined the professionals can know where the mutations of the cells are andattacks them directly. In relation with the paper review, the information of the study was very useful becauseit provided the necessary foundation to understanding the other articles I have evaluated.